{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:18:10Z","timestamp":1791235090371,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de recherche du Qu\u00e9bec Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.semnephrol.2023.151484","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T16:16:39Z","timestamp":1706112999000},"page":"151484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Matthew","family":"Ades","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vanassche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Eikelboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mavrakanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semnephrol.2023.151484_bib0001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0030-1248722","article-title":"Disorders of hemostasis associated with chronic kidney disease","volume":"36","author":"Jalal","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151484_bib0002","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.blre.2011.07.001","article-title":"Bleeding and thrombotic complications of kidney disease","volume":"25","author":"Pavord","year":"2011","journal-title":"Blood Rev"},{"issue":"8691","key":"10.1016\/j.semnephrol.2023.151484_bib0003","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0140-6736(90)90815-M","article-title":"Shear-induced platelet aggregation","volume":"335","author":"O'Brien","year":"1990","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.semnephrol.2023.151484_bib0004","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1016\/S0142-9612(03)00380-6","article-title":"On the influence of flow conditions and wettability on blood material interactions","volume":"24","author":"Spijker","year":"2003","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151484_bib0005","first-page":"57","article-title":"A descriptive report of errors and adverse events in chronic hemodialysis units","volume":"20","author":"Holley","year":"2006","journal-title":"Nephrol News Issues"},{"issue":"3 suppl 1","key":"10.1016\/j.semnephrol.2023.151484_bib0006","first-page":"S1","article-title":"Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology","volume":"17","author":"Jindal","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151484_bib0007","article-title":"Unfractionated heparins, LMWH, direct thrombin inhibitors\u2014global perspectives of dosing regimens, guidelines and healthcare economics","author":"Santos","year":"2023","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151484_bib0008","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ekir.2020.10.020","article-title":"A systematic review of the incidence of arrhythmias in hemodialysis patients undergoing long-term monitoring with implantable loop recorders","volume":"6","author":"Roberts","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151484_bib0009","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MNH.0000000000000634","article-title":"Direct oral anticoagulants in chronic kidney disease: An update","volume":"29","author":"Mavrakanas","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"17","key":"10.1016\/j.semnephrol.2023.151484_bib0010","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week","volume":"74","author":"Kumar","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.semnephrol.2023.151484_bib0011","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151484_bib0012","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1182\/blood-2014-10-604587","article-title":"Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor","volume":"125","author":"Puy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2023.151484_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151473","article-title":"Clotting of the extracorporeal circuit\u2014mechanisms of coagulation activation and the association between coagulation and inflammation","author":"Engelen","year":"2023","journal-title":"Semin Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151484_bib0014","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151484_bib0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151484_bib0016","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151484_bib0017","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2516.2000.00053.x","article-title":"Factor XI deficiency and its management","volume":"6","author":"Bolton-Maggs","year":"2000","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151484_bib0018","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: Cardiovascular perspectives","volume":"44","author":"De Caterina","year":"2023","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151484_bib0019","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151484_bib0020","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: A novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151484_bib0021","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151484_bib0022","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.semnephrol.2023.151484_bib0023","first-page":"B8","article-title":"Antithrombotic treatment with fesomersen vs. placebo in patients with ESKD on hemodialysis (ESKD-HD)","volume":"33","author":"Winkelmayer","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151484_bib0024","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/psp4.12663","article-title":"PK\/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151484_bib0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","article-title":"Monoclonal antibody therapeutics: History and future","volume":"12","author":"Buss","year":"2012","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151484_bib0026","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1538-7836.2012.04762.x","article-title":"Antidote strategies to reverse anticoagulation with TB-402, a long-acting partial inhibitor of factor VIII","volume":"10","author":"Tangelder","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151484_bib0027","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1160\/TH13-01-0066","article-title":"Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial","volume":"109","author":"Verhamme","year":"2013","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151484_bib0028","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.clinthera.2010.06.012","article-title":"Tolerability and pharmacokinetics of TB-402 in healthy male volunteers","volume":"32","author":"Verhamme","year":"2010","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151484_bib0029","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1538-7836.2011.04221.x","article-title":"Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: A dose-escalating, randomized, controlled trial","volume":"9","author":"Verhamme","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"13","key":"10.1016\/j.semnephrol.2023.151484_bib0030","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151484_bib0031","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151484_bib0032","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151484_bib0033","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1055\/s-0039-1692439","article-title":"The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials","volume":"45","author":"DeLoughery","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151484_bib0034","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151484_bib0035","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: Results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151484_bib0036","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jth.15744","article-title":"First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men","volume":"20","author":"Nowotny","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151484_bib0037","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151484_bib0038","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40262-022-01150-1","article-title":"Single-dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment","volume":"61","author":"Perera","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151484_bib0039","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151484_bib0040","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151484_bib0041","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151484_bib0042","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: The FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151484_bib0043","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151484_bib0044","unstructured":"Sharma M, and Hankey GJ. Efficacy and safety of the FXIa inhibitor milvexian for secondary stroke prevention: Final results of the AXIOMATIC-SSP dose-finding randomized trial. 2022. Presented at the European Society of Cardiology meeting in Barcelona on August 28, 2022."},{"issue":"10333","key":"10.1016\/j.semnephrol.2023.151484_bib0045","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): A multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151484_bib0046","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151484_bib0047","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151484_bib0048","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: A multinational population-based cohort study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann Intern Med"},{"issue":"10357","key":"10.1016\/j.semnephrol.2023.151484_bib0049","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): An international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.semnephrol.2023.151484_bib0050","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151484_bib0051","first-page":"874","article-title":"Risk and complications of venous thromboembolism in dialysis patients","volume":"33","author":"Molnar","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151484_bib0052","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2023.03.027","article-title":"Apixaban for stroke prevention in hemodialysis patients with nonvalvular atrial fibrillation","volume":"103","author":"Mavrakanas","year":"2023","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151484_bib0053","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151484_bib0054","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151484_bib0055","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151484_bib0056","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151484_bib0057","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.122.061647","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and end-stage renal disease: Lessons learned","volume":"146","author":"Benz","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151484_bib0058","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: A multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151484_bib0059","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: A multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151484_bib0060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: The AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151484_bib0061","first-page":"10","article-title":"Anticoagulation using factor XIa inhibition in patients receiving haemodialysis","volume":"11","author":"Winkelmayer","year":"2023","journal-title":"EMJ Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151484_bib0062","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/hae.13136","article-title":"Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficency","volume":"23","author":"Pike","year":"2017","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151484_bib0063","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.thromres.2015.06.025","article-title":"The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency","volume":"136","author":"Livnat","year":"2015","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151484_bib0064","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-0040-1715899","article-title":"Tissue factor-independent coagulation correlates with clinical phenotype in factor XI deficiency and replacement therapy","volume":"121","author":"Bertaggia Calderara","year":"2021","journal-title":"Thromb Haemost"},{"issue":"20","key":"10.1016\/j.semnephrol.2023.151484_bib0065","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/eurheartj\/ehad123","article-title":"Reversal agents for current and forthcoming direct oral anticoagulants","volume":"44","author":"van Es","year":"2023","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151484_bib0066","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/07853890600852898","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI)\u2014how does thrombin regulate fibrinolysis?","volume":"38","author":"Bouma","year":"2006","journal-title":"Ann Med"},{"issue":"222","key":"10.1016\/j.semnephrol.2023.151484_bib0067","doi-asserted-by":"crossref","first-page":"222ra217","DOI":"10.1126\/scitranslmed.3006804","article-title":"A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semnephrol.2023.151484_bib0068","doi-asserted-by":"crossref","unstructured":"Verbout NG LC, Markway BD, Wallisch M, Shatzel JJ and Tucker EI. A phase 2 trial evaluating the safety and antithrombotic efficacy of AB002, a first-in-class protein C activator, in end-stage renal disease patients on heparin-free hemodialysis. Presented at the ISTH meeting in London in (Accessed July 2022).","DOI":"10.1182\/blood-2021-148208"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:51:12Z","timestamp":1748343072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0270929523001948"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151484","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151484"}}